Vaksin COVID-19 Johnson & Johnson

Daripada Wikipedia, ensiklopedia bebas.
Jump to navigation Jump to search
Vaksin COVID-19 Johnson & Johnson
Johnson & Johnson COVID-19 vaccine developed by Janssen.jpg
Butiran vaksin
Penyakit sasaranSARS-CoV-2
Jenisviral
Terapi gen
Data klinikal
Nama dagangJanssen COVID-19 Vaccine,[1][2] COVID-19 Vaccine Janssen
Nama lain
Data lesen
Kaedah
pemberian
Intraotot
Kod ATC
Data fisiologi
Status perundangan
Status perundangan
  • KA: Schedule D; Authorized by interim order [5][6]
  • AS: Tidak disepakati (Penguatkuasaan Penggunaan Darurat)[7][1][8]
  • EU: Otorisasi pemasaran kondisional diberikan [9]
Data farmakokinetik
Pengecam
DrugBank
UNII
Data kimia dan fizikal
Halaman data

Vaksin COVID-19 Johnson & Johnson ialah vaksin COVID-19 vektor virus adenovirus manusia[10] yang dibangunkan oleh Janssen Vaccines di Leiden, Belanda,[11] dan syarikat induknya di Belgium, Janssen Pharmaceuticals,[12] anak syarikat milik syarikat farmaseutikal Amerika Syarikat Johnson & Johnson (J&J).[13][14]

Vaksin tersebut mengandungi bahan asas adenovirus manusia yang diubahsuai untuk membuat gen untuk mencipta protein terhadap virus SARS-CoV-2 yang menyebabkan COVID-19. Vaksin tersebut hanya diwajibkan satu dos dan tidak perlu disimpan beku.

Rujukan[sunting | sunting sumber]

  1. ^ a b "Janssen COVID-19 Vaccine- ad26.cov2.s injection, suspension". DailyMed. Dicapai pada 27 February 2021.
  2. ^ "Janssen COVID-19 Emergency Use Authorization (EUA) Official Website". Janssen. 28 February 2021. Dicapai pada 28 February 2021.
  3. ^ a b c d "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older ENSEMBLE Protocol VAC31518COV3001; Phase 3" (PDF). Janssen Vaccines & Prevention.
  4. ^ a b c d "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older ENSEMBLE 2 Protocol VAC31518COV3009; Phase 3" (PDF). Janssen Vaccines & Prevention.
  5. ^ "Regulatory Decision Summary – Janssen COVID-19 Vaccine – Health Canada". Health Canada. 5 March 2021. Dicapai pada 5 March 2021.
  6. ^ "Janssen COVID-19 Vaccine monograph" (PDF). Janssen. 5 March 2021.
  7. ^ "FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Berita). 27 February 2021. Dicapai pada 27 February 2021.
  8. ^ https://www.fda.gov/media/146303/download
  9. ^ "COVID-19 Vaccine Janssen EPAR". European Medicines Agency (EMA). 5 March 2021. Dicapai pada 16 March 2021.
  10. ^ "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)". ClinicalTrials.gov. Dicapai pada 30 January 2021.
  11. ^ "Leiden developed Covid-19 vaccine submitted to EMA for approval". 2021-02-16.
  12. ^ "Clinical trial COVID-19 vaccine candidate underway". Janssen Belgium (dalam bahasa Inggeris). Dicapai pada 2021-03-13.
  13. ^ "EMA recommends Johnson & Johnson Covid vaccine for approval; Developed in Leiden". NL Times.
  14. ^ Saltzman, Jonathan (12 March 2020). "Beth Israel is working with Johnson & Johnson on a coronavirus vaccine". The Boston Globe.

Pautan luar[sunting | sunting sumber]